Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05009329 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later May 2026 → Aug 2026
See other at-risk trials from Allist Pharmaceuticals, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from May 2026 to Aug 2026v7
  2. Enrollment target: estimated 311 to confirmed 315
    • Primary completion date: Dec 2025 to May 2026
    • Study completion date: Dec 2025 to Dec 2026
    v6
  3. Study Identification, Study Statusv5
  4. Lead sponsor: Jacobio Pharmaceuticals Co., Ltd. to Allist Pharmaceuticals, Inc.v4
  5. Enrollment target: 144 to 311v3 Show 9 more changesShow less
    • Primary endpoints: 2 to 3
    • Trial status: Recruiting to Active, Not Recruiting
    • Interventions: JAB-21822 (Drug), JAB-21822 (Drug) to JAB-21822 (Drug), JAB-21822 (Drug), JAB-21822 (Drug)
    • Eligibility criteria revised
    • Secondary endpoints revised (6)
    • Study description shortened, about 22 words
    • Site details revised
    • Study title revised
    • Study arms: 2 to 3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.
Trial Details
NCT Number NCT05009329
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 NSCLC, Solid Tumor
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 315 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov